Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

and pharmacokinetics of tezampanel

given once-daily for four consecutive days. Data from this multiple

dose trial are intended to support the continued development of

tezampanel for the treatment of migraine, as well as allow TorreyPines

to consider expanding the development of tezampanel into additional

chronic pain conditions.

-- Completed a Phase I multiple-dose clinical trial of NGX267 in

development for cognitive impairment associated with schizophrenia

(CIAS). NGX267 was found to be safe and well-tolerated. The clinical

trial also demonstrated that NGX267 increases salivary flow, which may

be beneficial in treating xerostomia, or dry mouth.

-- Extended the genetics discovery collaboration with Eisai Co., Ltd.

This agreement focuses on the discovery of Alzheimer's disease targets

using whole-genome family-based association screening. Under terms of

the agreement, TorreyPines received an upfront payment and continued

research funding in support of the program for an additional year.

Financial Results

Revenue for the three month period ended September 30, 2007 was $2.5 million compared to revenue of $2.5 million for the same period in 2006. Operating expenses for the quarter ended September 30, 2007 were $9.5 million, with $8.2 million attributable to research and development. This compares to operating expenses of $5.2 million and research and development expenses of $4.5 million for the same period last year. The Company reported a net loss for the quarter ended September 30, 2007 of $6.8 million compared to a net loss of $2.7 million for the same period last year.

Revenue for the nine month period ended September 30, 2007 was $7.4 million compared to revenue of $7.4 million for the same period in 2006. Operating expenses for the nine month period were $24.6 million, with $20.4 million attributabl
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 /PRNewswire/ ... has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. ... the pharmaceutical and biotechnology industries is anticipated. ... of drug development - from formulations for ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... treated and managed with the use of special anti-vascular endothelial growth factor agents ... many more patients, currently does not have a scientific protocol for the many ...
(Date:9/2/2015)... Biovista Inc. is glad to ... BeHEARD science challenge, a global competition hosted by the ... to the latest life science innovations and technologies. ... analytics capability to support Steven Laffoon and ... of Niemann-Pick Disease Type A (NPA), a rare and ...
(Date:9/2/2015)... Colo. , Sept. 2, 2015 Aytu ... on developing treatments for urological and related conditions, announced ... its planned private placement convertible note financing, raising a ... prior tranches totaling $3.175 million. ... "Proceeds from this private placement are intended to be ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
... Q4 2007 net revenues grew 29.8%, as compared to Q4 2006, to RMB45.7 ... million) - Q4 2007 net income grew 152.2%, as compared to Q4 2006, to RMB17.9 ... million (US$2.5 million), - 2007 fiscal year net revenues increased 41.0% year-over-year to RMB180.2 ... (US$24.7 million),- 2007 fiscal year net income grew 167.4% year-over-year to RMB81.5 million ...
... to rust plays a similarly corrosive role in our bodies. ... process, scientists know, that contributes to a host of diseases ... stroke to cancer and the inexorable process of aging. , ... the journal Nature, a team of University of Wisconsin-Madison scientists ...
... & Speciated Analysis Brings Unprecedented ... ... the EPA Method 6800 has been published in,January 2008 edition of the ... of US environmental statutes known as RCRA (Resource,Conservation and Recovery Act). This ...
Cached Biology Technology:3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 23SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 33SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 43SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 53SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 63SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 73SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 83SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 93SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 103SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 113SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 123SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 133SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 143SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 153SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 16Genetic pathway critical to disease, aging found 2Genetic pathway critical to disease, aging found 3Newly Published EPA RCRA Method 6800 Supports AIT Technology 2
(Date:9/2/2015)... Security of data and assets has ... organizations, telecommunications, hospitals, as well as individuals. Keys, ... used to prevent unauthorised access. Technological advancements resulted ... could gain access to secure premises after being ... devices and numeric codes. However, hackers also could ...
(Date:9/2/2015)... , September 2, 2015 ... security purpose implied in a system which uses ... voice, signature, iris, vein, DNA and finger print. ... forced to develop such system which provides high ... password, PIN, Patterns and tokens are vulnerable to ...
(Date:9/1/2015)... , Sept. 1, 2015  Automation and ... during airport passenger screening. This is the first ... screening process will become unintrusive. An assortment of ... on voluntary background investigations will transform the passenger ... & Sullivan, Global Airport Passenger Screening Market ...
Breaking Biology News(10 mins):Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4
... MASS. In a study that analyzed relationships ... University researcher has developed a new statistical model ... time periods where such information is not available. ... urban and environmental policy and planning at Tufts ...
... marijuana-like compounds called endocannabinoids alter genes and biological signals ... pregnancy and may contribute to pregnancy complications like preeclampsia. ... The Journal of Biological Chemistry offers new ... produced by the body disrupts the movement of early ...
... 2012 Using old deeds and witness trees, a ... the composition of the forests that covered today,s Monongahela ... "European Settlement-Era Vegetation of the Monongahela National Forest, West ... West Virginia University colleague answered questions about the composition ...
Cached Biology News:New model could help fill data gap in predicting historical air pollution exposure 2New model could help fill data gap in predicting historical air pollution exposure 3Study implicates marijuana use in pregnancy problems 2Old deeds, witness trees offer glimpse of pre-settlement forest in West Virginia 2Old deeds, witness trees offer glimpse of pre-settlement forest in West Virginia 3
... DeCypher combines enterprise-scale sequence analysis software with ... bioinformatics analyses. With DeCypher, you can perform searches ... ESTs vs NCBI NT database in under 6 ... to genomic DNA Use HMM analysis ...
...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
...
Biology Products: